BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37814415)

  • 21. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
    Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
    Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy.
    Qin HZ; Zhang MC; Le WB; Ren Q; Chen DC; Zeng CH; Liu L; Zuo K; Xu F; Liu ZH
    J Am Soc Nephrol; 2016 Oct; 27(10):3195-3203. PubMed ID: 26989120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
    Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
    PeerJ; 2022; 10():e14193. PubMed ID: 36248712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of serum anti-phospholipase A2 receptor antibody as a biomarker in membranous nephropathy: An experience from a tertiary care center of Eastern India.
    Mukherjee S; Kumar A; Maity P; Sengupta M; Basu K; Chaudhury AR; Bandopadhyay M; Chakraborty BC
    Indian J Pathol Microbiol; 2023; 66(2):269-277. PubMed ID: 37077067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.
    Timmermans SA; Abdul Hamid MA; Cohen Tervaert JW; Damoiseaux JG; van Paassen P;
    Am J Nephrol; 2015; 42(1):70-7. PubMed ID: 26344651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy.
    Zhang Q; Huang B; Liu X; Liu B; Zhang Y; Zhang Z; Hua J; Fan Y; Hu L; Meng M; Wu M; Wang L; Hu Z; Sun Z
    Sci Rep; 2017 Sep; 7(1):12049. PubMed ID: 28935926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.
    Hayashi N; Akiyama S; Okuyama H; Matsui Y; Adachi H; Yamaya H; Maruyama S; Imai E; Matsuo S; Yokoyama H
    Clin Exp Nephrol; 2015 Oct; 19(5):797-803. PubMed ID: 25492250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China.
    Guo H; Yao Y; Zhou J; Wang S; Wang Y; Zheng D
    Ren Fail; 2023; 45(2):2253922. PubMed ID: 37724562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.
    Jo HA; Hyeon JS; Yang SH; Jung Y; Ha H; Jeong CW; Kwak C; Kim Y; Lee H; Lee JP; Joo KW; Lim CS; Kim YS; Hwang GS; Kim DK
    Kidney Int; 2021 Feb; 99(2):443-455. PubMed ID: 32712166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
    Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
    J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
    Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
    Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A
    Tominaga K; Uchida T; Imakiire T; Itoh K; Shimazaki H; Nakanishi K; Kumagai H; Oshima N
    BMC Nephrol; 2018 May; 19(1):120. PubMed ID: 29792176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-phospholipase A2 Receptor Antibody in Differentiation and Prognostication of Membranous Nephropathy.
    Suthar KS; Vanikar AV; Patel RD; Kanodia KV; Nigam LA; Gandhi PA; Mehta AH
    Saudi J Kidney Dis Transpl; 2022; 33(2):280-287. PubMed ID: 37417180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.
    Oh YJ; Yang SH; Kim DK; Kang SW; Kim YS
    PLoS One; 2013; 8(4):e62151. PubMed ID: 23637987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.